首页> 外国专利> KIT OF TABLETTED ALIVE RECOMBINANT ORAL BIVACCINE AGAINST SMALLPOX AND HEPATITIS B AND METHOD FOR VACCINATION AT APPLYING THE KIT MENTIONED

KIT OF TABLETTED ALIVE RECOMBINANT ORAL BIVACCINE AGAINST SMALLPOX AND HEPATITIS B AND METHOD FOR VACCINATION AT APPLYING THE KIT MENTIONED

机译:针对小痘和乙型肝炎的片状活重组口腔生物疫苗的套件及应用该套件的疫苗接种方法

摘要

FIELD: medicine, immunology.;SUBSTANCE: the present innovation deals with specific prophylaxis of smallpox and viral hepatitis B. The kit contains two tablets each contains stabilizing additives, a filler and lyophilized alive viral material worked out based upon recombinant VOV strain at typical VOV properties expressing proteins preS2-S and HBs virus of hepatitis B virus, the first immunizing dosage corresponds to minimal quantity of viral material being sufficient to obtain weak immune response in the body in case of insignificant at insignificant reactogenicity, and immunizing dosage of the second - maximal quantity of viral material that causes pronounced and prolong immune response in the body at no negative side action. The technique of applying the kit of bivaccine tablets, first, one should use the 1st tablet at minimal dosage of bivaccine, as for the 2nd tablet - with maximal dosage of bivaccine it should be taken till the moment of developing humoral answer (in 7-14 d) after injecting the 1st tablet at minimal immunizing dosage of bivaccine. The innovation enables to create stable immunity.;EFFECT: higher efficiency.;4 cl, 5 ex, 6 tbl
机译:领域:医学,免疫学;研究方向:本发明涉及天花和乙型肝炎病毒的具体预防。该试剂盒包含两片片剂,每片均含有稳定添加剂,填充剂和冻干的活病毒材料,这些材料是基于典型VOV的重组VOV菌株制成的乙型肝炎病毒的preS2-S和HBs病毒蛋白表达特性,第一个免疫剂量对应的最小量的病毒物质足以在机体反应原性不明显的情况下在体内获得弱的免疫反应,而第二个免疫剂量则是最大数量的病毒物质,可在体内产生显着且持久的免疫反应,且无副作用。使用bivaccine片剂套件的技术,首先,应该以最小剂量的bivaccine使用1 st 片剂,就如2 片剂一样-最大剂量为在以最小疫苗剂量的Bivaccine注射1 st 片剂后,应服用bivaccine直至出现体液应答的时刻(7-14 d)。这项创新技术可以产生稳定的免疫力;效果:更高的效率; 4 cl,5 ex,6 tbl

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号